Yeztugo in India
Pre-exposure prophylaxis to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35 kg · Infectious disease (HIV pre-exposure prophylaxis)
Yeztugo - overview
Pre-exposure prophylaxis to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35 kg product mapping. It is a long-acting HIV-1 capsid inhibitor (subcutaneous injection, twice yearly) approved by the US FDA in 2025 and may be accessible to patients in India through a Named Patient Program or personal-import pathway.
Access in India
India's CDSCO permits import of unapproved drugs under Rule 36 for personal use by patients with a prescription from a registered medical practitioner. Named Patient import is common for rare-disease indications.
How Reserve Meds coordinates access in India
- Patient or treating physician submits a request.
- We verify clinical appropriateness and India-specific eligibility.
- Treating physician in India issues prescription and clinical justification.
- Country-specific NPP/personal-import forms are prepared and filed.
- We source Yeztugo from a DSCSA-compliant US specialty wholesaler.
- Cold-chain shipment to the patient's physician or hospital pharmacy in India.
Typical timeline for India
End-to-end, most requests are completed in 2-6 weeks. India's tier 1 regulatory maturity typically supports fast processing times.
What patients and physicians in India ask
- Is the pathway legal in India? Yes - it operates under India's established NPP or personal-import framework.
- Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
- What physician credentials do I need? A licensed physician in India able to issue the prescription and clinical justification.
- What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
- Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.